About US
Contact us
-
Bayer, others fined $15.9M by Romanian competition authorityThe Romanian Competition Council has wrapped up an ongoing investigation into alleged antitrust practices by Bayer ($BAY), Sintofarmand 9 distributors. The result: a combined €12 million in fines the2012/3/21
-
Indian government defends country's generics industryA major government official in India is blasting what he says are attempts to target the country's generic drug industry as substandard or inferior. As reported in The Economic Times,he's also seeking2012/3/21
-
Roche exec expects 'limited' rebound for pharmaDon't look for a fabulous rebound in drug sales once the patent cliff is past. So says Roche COO Pascal Soriot, who expects a paltry 2% to 3% growth in the U.S. market and stagnant sales in Europe ove2012/3/20
-
GSK to eavesdrop on social-media chatter with IT dealGlaxoSmithKline ($GSK) wants to know what consumers are saying about it online so that it can do a better job with its digital marketing. So, the London-based drug giant has inked a multimillion-dolla2012/3/20
-
Novartis persuades NICE to endorse GilenyaThe U.K.'s cost-effectiveness watchdog has changed its mind about Gilenya. The National Institute for Health and Clinical Excellence at first rejected the Novartis ($NVS) multiple sclerosis pill, in s2012/3/19
-
Can European pharma's cash flow cover buyback plans?It's no secret Big Pharma is all about dividends and stock buybacks right now. With short-term earnings under pressure from patent expirations, drugmakers have been using these promises to keep invest2012/3/19
-
Stada stymied in bids for Russian M&AGermany's Stada wants to expand in Russia. But attempts to buy Russian drugmakers have so far failed--despite months of effort--leaving the company with a big debt burden and stagnant home market, Reu2012/3/16
-
J&J's Weldon due for $143M retirement packageA 40-year career at Johnson & Johnson ($JNJ) can really pay off, especially if you cap it with a 10-year stint as CEO. That's the company's explanation for the whopping $143 million retirement pac2012/3/16
-
J&J's Weldon due for $143M retirement packageA 40-year career at Johnson & Johnson ($JNJ) can really pay off, especially if you cap it with a 10-year stint as CEO. That's the company's explanation for the whopping $143 million retirement pac2012/3/16
-
Rosa PK/PD Collaboration with Pfizer to be Presented at ASCPT 2012SAN CARLOS,, CA, March 09, 2012 /24-7PressRelease/ -- Rosa & Co. LLC, a drug development advisory firm with expertise in PK/PD and drug-disease modeling and simulation, today announced that result2012/3/15